原始来源记录
决策级顶线结果
Opus Genetics:OPGx-BEST1 1/2期第1队列3个月顶线数据
Low-dose Cohort 1 data show 75% of evaluable patients met the FDA-aligned microperimetry endpoint and 80% had structural improvement. Cohort 2 is over-enrolled; 6-month Cohort 1 and 3-month Cohort 2 data are now expected in Q2 2027, with pivotal trial dosing slated to begin in 2027.
关键事实
- 申报时间
- 2026年9月11日 11:48
- 事件
- 顶线结果
- 方向
- 积极
- 来源
- SEC 8-K
- 可信度
- 有来源
- 队列1剂量
- 1.5×10^9 vg/眼
- 队列2剂量
- 4.5×10^9 vg/眼
- 最佳矫正视力改善
- 5名参与者中3名
- 队列2顶线数据
- 2027年第二季度
- 队列2入组
- 8名参与者
- 结构改善
- 5名参与者中4名
- 队列2给药完成
- 2026年第四季度
- 微视野计改善
- 4名参与者中3名
来源摘录
EX-99.1 2 ef20081922_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate，” “expect，” “intend，” “aim，” “may，” “ongoing，” “plan，” “potential，” “predict，” “project，” “should，” “will，” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Such statements include, but are not limited to, statements related to our continued clinical development, clinical results, preclini